LOS ANGELES, Nov. 3, 2025 /PRNewswire/ — The DJS Law Group announces that it is investigating claims on behalf of investors of aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of the securities laws.
INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. On September 15, 2025, Reuters reported that, “aTyr Pharma said on Monday its experimental drug had failed to meet the main goal in a late-stage study testing it in patients with a type of lung disease known as pulmonary sarcoidosis, which impacts the lungs and lymph nodes.” Based on this news, shares of aTyr traded down by more than 81% in morning trading on the same day.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]
SOURCE DJS Law Group LLP
